Evidence map›Paper›PMID 41801221›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Phase Separation of NFIB Suppresses SLC3A2-Mediated Ferroptosis in Castration-Resistant Prostate Cancer.

Qiunuo Li, Danyang Chen, Yongzhen Xia, Yili Long, Nan Huang, Rongna Li, Mengting Shi, Mairehaba Kadier, Huafeng Luo, Xiaohui Chen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Qiunuo LiDepartment of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China.
Danyang ChenAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong, China.
Yongzhen XiaDepartment of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China.
Yili LongDepartment of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China.
Nan HuangDepartment of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China.
Rongna LiDepartment of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China.
Mengting ShiDepartment of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China.
Mairehaba KadierDepartment of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China.
Huafeng LuoAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong, China.
Xiaohui ChenDepartment of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China.
Hao LiuAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong, China.
Guanmin JiangDepartment of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China.ORCID https://orcid.org/0000-0002-0397-1860

Funding

Fundamental and Applied Basic Research Funds of Guangdong Province 2023A1515110114Guangdong Provincial Clinical Research Center for Laboratory Medicine 2023B110008National Natural Science Foundation of China 82272388National Natural Science Foundation of China 82403962Natural Science Foundation of Guangdong Province 2024A1515012898The Wu Jieping Medical Foundation Special Research 320.6750.2024-06-92
6 · The paper itself

Abstract

Castration-resistant prostate cancer (CRPC) is frequently resistant to conventional therapies and lacks effective treatment options. Although CRPC cells exhibit sensitivity to ferroptosis inducers, the mechanisms regulating ferroptosis remain unclear. Here, we identify nuclear factor I/B (NFIB) as a critical suppressor of ferroptosis in CRPC. NFIB is upregulated in CRPC tissues and cell lines, positively correlating with SLC3A2, a critical subunit of System Xc

Indexed as

Amino Acid Transport System y+FerroptosisNFI Transcription FactorsProstatic Neoplasms, Castration-ResistantAnimalsCell Line, TumorHumansMaleMiceAmino Acid Transport System y+NFI Transcription Factorscastration‐resistant prostate cancerferroptosisliquid–liquid phase separationNFIBSLC3A2

Identifiers

PMID41801221
PMCPMC13159144

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.